MiniMed Group Inc (NASDAQ:MMED – Get Free Report) saw a large decline in short interest in the month of October. As of October 30th, there was short interest totaling 9,813,734 shares, a decline of 52.8% from the October 15th total of 20,793,160 shares. Currently, 3.5% of the company’s shares are sold short. Based on an average daily trading volume, of 10,245,967 shares, the days-to-cover ratio is currently 1.0 days.
Institutional Trading of MiniMed Group
Institutional investors have recently added to or reduced their stakes in the business. Healthcare of Ontario Pension Plan Trust Fund raised its position in MiniMed Group by 358.7% in the third quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,720,000 shares of the company’s stock valued at $33,488,000 after purchasing an additional 1,345,000 shares during the period. BlackRock Inc. lifted its stake in shares of MiniMed Group by 7,527.5% during the second quarter. BlackRock Inc. now owns 1,996,489 shares of the company’s stock worth $29,848,000 after purchasing an additional 1,970,314 shares in the last quarter. Boston Partners boosted its position in shares of MiniMed Group by 0.6% in the third quarter. Boston Partners now owns 908,007 shares of the company’s stock worth $17,695,000 after buying an additional 5,648 shares during the period. First Trust Advisors LP boosted its position in shares of MiniMed Group by 124.7% in the third quarter. First Trust Advisors LP now owns 822,845 shares of the company’s stock worth $16,021,000 after buying an additional 456,577 shares during the period. Finally, State Street Corp grew its stake in shares of MiniMed Group by 73.0% in the third quarter. State Street Corp now owns 697,580 shares of the company’s stock valued at $13,582,000 after buying an additional 294,291 shares in the last quarter.
MiniMed Group Price Performance
Shares of MiniMed Group stock traded up $0.66 during trading hours on Monday, hitting $18.65. The company’s stock had a trading volume of 10,535,113 shares, compared to its average volume of 8,750,697. The business has a fifty day moving average of $19.51 and a 200 day moving average of $16.74. MiniMed Group has a 1-year low of $10.65 and a 1-year high of $24.43.
Analysts Set New Price Targets
A number of research firms recently issued reports on MMED. Bank of America boosted their target price on shares of MiniMed Group from $24.00 to $28.00 and gave the company a “buy” rating in a report on Wednesday, September 2nd. Barclays decreased their price target on shares of MiniMed Group from $22.00 to $20.00 and set an “equal weight” rating on the stock in a report on Friday. BTIG Research boosted their price objective on shares of MiniMed Group from $25.00 to $28.00 and gave the company a “buy” rating in a research note on Tuesday, September 1st. Weiss Ratings upgraded MiniMed Group from a “sell (d-)” rating to a “sell (d)” rating in a report on Wednesday, September 9th. Finally, Morgan Stanley increased their target price on MiniMed Group from $19.00 to $21.00 and gave the stock an “overweight” rating in a research report on Thursday, September 3rd. Fourteen investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $24.12.
View Our Latest Analysis on MMED
MiniMed Group Company Profile
MiniMed Group focuses on diabetes technology, developing products and services to help people manage insulin-dependent diabetes. Its offerings include insulin pumps, continuous glucose monitoring systems, infusion sets and software for tracking glucose and coordinating insulin delivery. The business is known for automated insulin-delivery systems that use glucose readings to help adjust insulin delivery, including products in the MiniMed 780G system line. Its technologies are intended for use by people with diabetes and the clinicians who support their care.
See Also
- Five stocks we like better than MiniMed Group
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for MiniMed Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiniMed Group and related companies with MarketBeat.com's FREE daily email newsletter.
